Exscientia and Recursion Merge to Form AI Drug Discovery Giant
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
- Latest
- Trending
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Dyne Therapeutics appoints new CEO, George Eliades, and other key executives as it prepares for growth. Robert Coffin to step ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.